Martin Cevallos-Cueva, Carlos Alberto Monteiro Leitão Neto, Devanie Martani, Laura Ghanem, Camila Almeida Sardinha, Daniela Lucía Mendoza-Millán, Cristina Sicorschi Gutu, Victor Barreiros Pungirum, Peter Chien
{"title":"非甾体局部芳香烃受体激动剂治疗特应性皮炎的安全性和有效性：随机对照试验的系统回顾和元分析》。","authors":"Martin Cevallos-Cueva, Carlos Alberto Monteiro Leitão Neto, Devanie Martani, Laura Ghanem, Camila Almeida Sardinha, Daniela Lucía Mendoza-Millán, Cristina Sicorschi Gutu, Victor Barreiros Pungirum, Peter Chien","doi":"10.1111/ajd.14485","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Current first-line topical treatments for atopic dermatitis (AD) are often limited by concerns related to age, systemic absorption, especially when applied to large body surface areas or under maximal usage conditions and undesirable adverse events (AEs), highlighting the need for alternative therapies.</p><p><strong>Methods: </strong>We performed a systematic review and meta-analysis of seven randomised controlled trials (RCT) comparing topical aryl hydrocarbon receptor agonists (TAHRA), including tapinarof and benvitimod cream, to vehicle at different concentrations and application frequencies in patients with AD, which evaluated outcomes such as Investigator Global Assessment (IGA) scores/Validated Investigator's Global Assessment (vIGA), the Eczema Area and Severity Index (EASI-75), change from baseline in body surface area (BSA) and pruritus score (PS) and safety profiles.</p><p><strong>Results: </strong>A total of 1631 patients, 1086 received TAHRA, while 545 received vehicle. Overall, TAHRA led to a significant improvement in the IGA/vIGA scores (RR 2.38; 95% CI 1.68 to 3.37; p < 0.0001), EASI-75 (RR 2.94; 95% CI 2.07 to 4.17; p < 0.00001). Similar findings were observed for mean change from baseline in BSA% (MD -6.08; 95% CI -8.00 to -4.16; p < 0.00001), and PS (Std MD -0.90; 95% CI -1.41 to -0.39; p = 0.0006). The incidence of AE was significantly higher in the TAHRA group (RR 1.48; 95% CI: 1.19-1.85; p = 0.0005). We found no significant difference in the incidence of serious adverse events (SAEs) (RR of 1.51; 95% CI: 0.34-6.64; p = 0.59). Treatment-emergent adverse events (TEAEs), such as folliculitis, were more frequent in the TAHRA group (RR 8.06; 95% CI: 2.75-23.60; p = 0.0001).</p><p><strong>Conclusion: </strong>Our findings support the efficacy of TAHRA among different metrics with minimal and tolerable AEs and its use as a valuable new non-steroidal option for the treatment of AD.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and Efficacy of Non-Steroidal Topical Aryl Hydrocarbon Receptor Agonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.\",\"authors\":\"Martin Cevallos-Cueva, Carlos Alberto Monteiro Leitão Neto, Devanie Martani, Laura Ghanem, Camila Almeida Sardinha, Daniela Lucía Mendoza-Millán, Cristina Sicorschi Gutu, Victor Barreiros Pungirum, Peter Chien\",\"doi\":\"10.1111/ajd.14485\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Current first-line topical treatments for atopic dermatitis (AD) are often limited by concerns related to age, systemic absorption, especially when applied to large body surface areas or under maximal usage conditions and undesirable adverse events (AEs), highlighting the need for alternative therapies.</p><p><strong>Methods: </strong>We performed a systematic review and meta-analysis of seven randomised controlled trials (RCT) comparing topical aryl hydrocarbon receptor agonists (TAHRA), including tapinarof and benvitimod cream, to vehicle at different concentrations and application frequencies in patients with AD, which evaluated outcomes such as Investigator Global Assessment (IGA) scores/Validated Investigator's Global Assessment (vIGA), the Eczema Area and Severity Index (EASI-75), change from baseline in body surface area (BSA) and pruritus score (PS) and safety profiles.</p><p><strong>Results: </strong>A total of 1631 patients, 1086 received TAHRA, while 545 received vehicle. Overall, TAHRA led to a significant improvement in the IGA/vIGA scores (RR 2.38; 95% CI 1.68 to 3.37; p < 0.0001), EASI-75 (RR 2.94; 95% CI 2.07 to 4.17; p < 0.00001). Similar findings were observed for mean change from baseline in BSA% (MD -6.08; 95% CI -8.00 to -4.16; p < 0.00001), and PS (Std MD -0.90; 95% CI -1.41 to -0.39; p = 0.0006). The incidence of AE was significantly higher in the TAHRA group (RR 1.48; 95% CI: 1.19-1.85; p = 0.0005). We found no significant difference in the incidence of serious adverse events (SAEs) (RR of 1.51; 95% CI: 0.34-6.64; p = 0.59). Treatment-emergent adverse events (TEAEs), such as folliculitis, were more frequent in the TAHRA group (RR 8.06; 95% CI: 2.75-23.60; p = 0.0001).</p><p><strong>Conclusion: </strong>Our findings support the efficacy of TAHRA among different metrics with minimal and tolerable AEs and its use as a valuable new non-steroidal option for the treatment of AD.</p>\",\"PeriodicalId\":8638,\"journal\":{\"name\":\"Australasian Journal of Dermatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australasian Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajd.14485\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajd.14485","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：目前针对特应性皮炎（AD）的一线局部治疗通常受到年龄、全身吸收等因素的限制，特别是当应用于大面积体表或在最大使用条件下以及不良事件（ae）时，突出了替代疗法的必要性。方法:我们对7项随机对照试验（RCT）进行了系统回顾和荟萃分析，比较了包括tapinarof和benvimod乳膏在内的局部芳烃受体激动剂（TAHRA）在不同浓度和使用频率下对AD患者的影响，评估了研究者总体评估（IGA）评分/有效研究者总体评估（vIGA）、湿疹面积和严重程度指数（EASI-75）等结果。与基线相比体表面积（BSA）和瘙痒评分（PS）的变化和安全性概况。结果：1631例患者中，1086例患者接受了TAHRA治疗，545例患者接受了vehicle治疗。总体而言，TAHRA导致IGA/vIGA评分显著改善(RR 2.38；95% CI 1.68 ~ 3.37；结论：我们的研究结果支持TAHRA在不同指标中具有最小和可耐受的不良事件的疗效，并将其作为治疗AD的有价值的新的非甾体药物选择。
Safety and Efficacy of Non-Steroidal Topical Aryl Hydrocarbon Receptor Agonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Background: Current first-line topical treatments for atopic dermatitis (AD) are often limited by concerns related to age, systemic absorption, especially when applied to large body surface areas or under maximal usage conditions and undesirable adverse events (AEs), highlighting the need for alternative therapies.
Methods: We performed a systematic review and meta-analysis of seven randomised controlled trials (RCT) comparing topical aryl hydrocarbon receptor agonists (TAHRA), including tapinarof and benvitimod cream, to vehicle at different concentrations and application frequencies in patients with AD, which evaluated outcomes such as Investigator Global Assessment (IGA) scores/Validated Investigator's Global Assessment (vIGA), the Eczema Area and Severity Index (EASI-75), change from baseline in body surface area (BSA) and pruritus score (PS) and safety profiles.
Results: A total of 1631 patients, 1086 received TAHRA, while 545 received vehicle. Overall, TAHRA led to a significant improvement in the IGA/vIGA scores (RR 2.38; 95% CI 1.68 to 3.37; p < 0.0001), EASI-75 (RR 2.94; 95% CI 2.07 to 4.17; p < 0.00001). Similar findings were observed for mean change from baseline in BSA% (MD -6.08; 95% CI -8.00 to -4.16; p < 0.00001), and PS (Std MD -0.90; 95% CI -1.41 to -0.39; p = 0.0006). The incidence of AE was significantly higher in the TAHRA group (RR 1.48; 95% CI: 1.19-1.85; p = 0.0005). We found no significant difference in the incidence of serious adverse events (SAEs) (RR of 1.51; 95% CI: 0.34-6.64; p = 0.59). Treatment-emergent adverse events (TEAEs), such as folliculitis, were more frequent in the TAHRA group (RR 8.06; 95% CI: 2.75-23.60; p = 0.0001).
Conclusion: Our findings support the efficacy of TAHRA among different metrics with minimal and tolerable AEs and its use as a valuable new non-steroidal option for the treatment of AD.
期刊介绍：
Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
